Peripheral blood stem cell mobilization and engraftment after autologous stem cell transplantation with biosimilar rhG-CSF.

@article{Remnyi2014PeripheralBS,
  title={Peripheral blood stem cell mobilization and engraftment after autologous stem cell transplantation with biosimilar rhG-CSF.},
  author={P{\'e}ter Rem{\'e}nyi and L{\'a}szl{\'o} Gopcsa and Imelda Marton and Marienn R{\'e}ti and Gabor Mikala and M{\'o}nika Pető and Anik{\'o} Barta and Arp{\'a}d B{\'a}tai and Zita Farkas and Zita Borb{\'e}nyi and Zolt{\'a}n Csukly and I Bod{\'o} and J{\'a}nos F{\'a}bi{\'a}n and Agnes Kir{\'a}ly and Lilla Lengyel and Kl{\'a}ra Piukovics and Eva Torb{\'a}gyi and Tamas Masszi},
  journal={Advances in therapy},
  year={2014},
  volume={31 4},
  pages={451-60}
}
INTRODUCTION Biosimilar versions of filgrastim [recombinant human granulocyte colony-stimulating factor (rhG-CSF)] are now widely available. To date, biosimilar rhG-CSF has demonstrated a comparable quality, safety and efficacy profile to the originator product (filgrastim [Neupogen(®)], Amgen Inc., CA, USA) in the prevention and management of neutropenia. Biosimilar rhG-CSFs have also been used to induce peripheral blood stem cell (PBSC) mobilization in patients undergoing autologous stem cell… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS